Fig. 7
G6PD pharmacological inhibition blocks DCBLD1-induced increases in cell proliferation, migration, and invasion. A HeLa and C33A cells, which were stably expressing both the vector and OV-DCBLD1, were treated with 6-AN (120 nM) and rapamycin (25 nM) either individually or in combination. B Cell viability was determined through CCK8 assays, while the cell proliferation rate was determined using the clone formation assay. C, D Transwell migration and invasion assays were performed on HeLa and C33A cells, stably expressing the vector and OV-DCBLD1 after 24 h treatment with 6-AN (120 nM) and Rapamycin (25 nM) individually or in combination. E A total of 1 × 106 HeLa-vector and HeLa-OV-DCBLD1 cells were injected subcutaneously into the right abdomen of 4- to 5-week-old female nude mice (n = 5). Images show xenograft tumors in nude mice after treatment with 4 mg/kg/2d 6-An and 2 mg/kg/2d Rapamycin individually or in combination. Tumor size was measured every 5 days for 3 weeks. Scale bars: 10 mm. n = 6 mice per group. Tumor growth curves of the different groups. Weight of the excised tumors in each group. Data are presented as mean ± SD. Statistical significance was assessed using a one-way ANOVA with the Brown-Forsythe test (A), a two-way ANOVA with Šídák's multiple comparisons test (B, C, and D; E for tumor weight), and a one-way ANOVA with Tukey's multiple comparisons test (E for tumor volume). (****, p < 0.0001; **, p < 0.01; *, p < 0.05). Scale bar: 50 µm